Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: Implications for therapy with an emphasis on clinical pharmacokinetics

Paediatric Drugs

Volumn 3, Issue 10, 2001, Pages 733-761

  Singh, J ^a   Burr, B ^a   Stringham, D ^a   Arrieta, A ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFOPERAZONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; ERYTHROMYCIN; FLUCONAZOLE; HETEROCYCLIC COMPOUND; ITRACONAZOLE; MACROLIDE; MONOBACTAM DERIVATIVE; NAFCILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOGRAMIN DERIVATIVE; SULTAMICILLIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; BACTERIAL INFECTION; CHILD; CHILD HOSPITALIZATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; MYCOSIS; PENICILLIN ALLERGY; PHLEBITIS; PRIORITY JOURNAL; REVIEW;

EID: 0034764779     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103100-00003     Document Type: Review

References (369)

1. Neonatal therapy
2. Principles of drug therapy
3. Principles of drug biodisposition in the neonate: A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part 1)
4. The newborn infant
5. Challenges in the management of serious infections in paediatric patients
6. Antimicrobial agents: Penicillins, cephalosporins and other beta-lactam antibiotics
7. B-lactam antibiotics in the newborn
8. Clinical pharmacokinetics of antibacterial drugs in neonates
9. Pharmacokinetics of anti-infective agents in paediatric patients
10. The penicillins
11. Penicillins: A current review of their clinical pharmacology and therapeutic use
12. Clinical pharmacokinetics in newborns and infants: Age-related differences and therapeutic implications
13. Clinical pharmacology of penicillins in newborn infants
14. Clinical pharmacology of methicillin in neonates
15. Pharmacokinetics of methicillin in patients with cystic fibrosis
16. Clinical and pharmacokinetic evaluation of nafcillin in infants and children
17. Pharmacokinetics and cerebrospinal fluid concentration of nafcillin in paediatric patients undergoing cerebrospinal fluid shunt placement
18. Pharmacokinetics of nafcillin in infants with low birth weights
19. The effect of probenecid on nafcillin disposition
20. Sulbactam/ampicillin: A new beta-lactamase inhibitor/beta-lactam antibiotic combination
21. Pharmacokinetics of ampicillin and sulbactam in paediatric patients
22. Sulbactam/ampicillin: A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use
23. Pharmacokinetics of sulbactam/ampicillin in humans: A review
24. The beta-lactamase inhibitors: Clinical pharmacology and rational application to combination antibiotic therapy
25. Clinical pharmacology and efficacy of mezlocillin in paediatric patients with malignancy
26. Mezlocillin pharmacokinetics in paediatric oncology patients
27. Pharmacokinetic studies of mezlocillin in newborn infants
28. Piperacillin pharmacokinetics in paediatric patients
29. Pharmacokinetics of intravenously administered piperacillin in preadolescent children
30. Pharmacokinetic study of piperacillin in newborns relating to gestational and postnatal age
31. Piperacillin/tazobactam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential
32. A review of the pharmacokinetic and pharmacodynamic characteristics of beta-lactam/beta-lactamase inhibitor combination antibiotics in premature infants
33. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children
34. Pharmacokinetic-based ticarcillin/clavulanic acid close recommendations for infants and children
35. Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis
36. A reassessment of ticarcillin/clavulanic acid dose recommendations for infants, children and adults
37. Clinical pharmacology and efficacy of ticarcillin in infants and children
38. Clinical pharmacology of ticarcillin in newborn infants: Relation to age, gestational age, and weight
39. Cephalosporin antimicrobial agents and related compounds
40. Steady-state moxalactam kinetics: Comparisons with other cephalosporins
41. Pharmacokinetics of cefazolin compared with four other cephalosporins
42. A study of serum levels of cefazolin following a single intravenous dose in newborns, immature infants, and younger children
43. Experience with cefazolin: An overall summary of pharmacologic and clinical trials in man
44. Pharmacokinetics and tissue concentrations of cefazolin in paediatric patients undergoing gastrointestinal surgery
45. Comparative distribution kinetics of cefazolin and tobramycin in children
46. Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based upon physiological pharmacokinetic concepts
47. Clinical and pharmacologic evaluation of cefazolin in children
48. Comparative pharmacokinetics and clinical experience with a new cephalosporin-derivative: Cefazolin
49. Clinical pharmacokinetics of the third generation cephalosporins
50. Considerations in dosage selection for third generation cephalosporins
51. Clinical and pharmacokinetics evaluation of cefotetan in treatment of urinary tract infections in the neonatal period
52. Cefotetan in the treatment of urinary tract infections in the neonatal period: Clinical and pharmacologic evaluation
53. Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function
54. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination
55. Cefoxitin: A review of its antibacterial activity, pharmacological properties and therapeutic use
56. Some experiences in the field of paediatrics with cefoxitin treatment by intravenous injections
57. Laboratory and clinical studies in paediatric field
58. Basic and clinical studies on cefoxitin in paediatrics
59. Cefuroxime: A review of its antibacterial activity, pharmacological properties and therapeutic use
60. Cefuroxime: Antimicrobial activity, human pharmacokinetics and therapeutic efficacy
61. Pharmacokinetics of cefuroxime axetil suspension in infants and children
62. Pharmacokinetics of cefuroxime in infants and children with bacterial meningitis
63. Clinical pharmacokinetics studies on cefuroxime
64. Cefoperazone pharmacokinetics in acute childhood meningitis
65. Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis
66. Cefotaxime dosage in infants and children
67. Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates
68. Pharmacokinetics of ceftizoxime
69. Pharmacokinetics of ceftazidime in newborn infants
70. Ceftazidime: An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy
71. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime
72. Clinical pharmacology of ceftazidime in paediatrics
73. A preliminary pharmacokinetics study of ceftazidime in premature, newborn and small infants
74. Pharmacokinetics of ceftazidime in children and newborn infants: Study in 14 patients and review and review of the literature
75. Fundamental and clinical studies on ceftazidime in the field of paediatrics
76. Age-related characteristics of ceftazidime pharmacokinetics in children
77. Laboratory and clinical studies on ceftizoxime in the field of paediatrics
78. Ceftizoxime disposition in neonates and infants during the first six months of life
79. Clinical efficacy and pharmacokinetics of ceftizoxime in neonates with meningitis and septicemia
80. Single-dose plasma and cerebrospinal fluid pharmacokinetics of ceftriaxone in infants and children
81. Single-dose pharmacokinetics of ceftriaxone in infants and young children
82. Pharmacokinetics of ceftriaxone in paediatric patients with meningitis
83. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics
84. Ceftriaxone: A reappraisal of its antibacterial activity and pharmacokinetic properties and an update on its therapeutic use with particular reference to once-daily administration
85. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects
86. Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children
87. Cefepime
88. Cefepime clinical pharmacokinetics
89. Cefpirome clinical pharmacokinetics
90. Pharmacokinetics of cefpirome in paediatric patients
91. Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers
92. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin
93. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis
94. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life
95. Imipenem/cilastatin: A reappraisal of its antibacterial activity, pharmacologic properties and therapeutic efficacy
96. Disposition of radiolabeled imipenem and cilastatin in normal human volunteers
97. Single-dose pharmacokinetics of imipenem in children
98. Pharmacokinetic determinants of carbapenem therapy in neonates and children
99. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalised infants and children
100. Meropenem clinical pharmacokinetics
101. The pharmacokinetics of meropenem
102. Meropenem pharmacokinetics in pre-term and full-term neonates
103. Meropenem: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy
104. The pharmacokinetics of meropenem in volunteers
105. Pharmacokinetics of meropenem and its metabolite (ICI 213,689) in healthy subjects with known renal metabolism of imipenem
106. Single-dose pharmacokinetics of aztreonam in paediatric patients
107. Aztreonam: A review of the clinical experience and potential uses in paediatrics
108. Clinical pharmacokinetics of aztreonam
109. Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis
110. Pharmacokinetics and plasma bactericidal activity of aztreonam in low-birth-weight infants
111. Pharmacokinetics and renal tolerance of aztreonam in premature infants
112. New cephalosporins
113. Cefotaxime: A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections
114. Delayed cerebrospinal fluid sterilisation and adverse outcome of bacterial meningitis in infants and children
115. Cefotaxime use in paediatric infections
116. Delayed cerebrospinal fluid sterilisation, in vitro bactericidal activities, and side effects of selected beta-lactams
117. Increasing enterobacter bacteremia in paediatric patients
118. Cefepime
119. Pharmacokinetic determinants of carbapenem therapy in neonates and children
120. Imipenem/cilastatin: A reappraisal of its antibacterial activity, pharmacokinetics, and therapeutic efficacy
121. Meropenem: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy
122. Use of meropenem in the treatment of serious infections in children: Review of the current literature
123. Meropenem versus cefotaxime-based therapy for the initial treatment of infants and children hospitalised with non-CNS infections
124. Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalised paediatric patients
125. Use of carbapenems and other antibiotics for pulmonary infections in patients with cystic fibrosis
126. Empirical treatment of fever in neutropenic children: The role of the carbapenems
127. Imipenem/cilastatin treatment of bacterial meningitis in children
128. Symposium on antimicrobial agents, part XII: Vancomycin
129. Pharmacokinetics of vancomycin
130. Effects of hepatic function on vancomycin clinical pharmacology
131. Vancomycin pharmacokinetics in a patient population: Effect of age, gender, and bodyweight
132. The aminoglycosides
133. Cerebrospinal fluid penetration of vancomycin in bacterial meningitis
134. Pharmacokinetics of gentamicin in children and adults
135. An overview of paediatric experience
136. Tobramycin and gentamicin concentration in the serum of normal and anephric patients
137. Pharmacokinetics of amikacin during haemodialysis and peritoneal dialysis
138. Autoradiographic localisation of [3H]gentamicin in the proximal renal tubules of mice
139. Penetration of parenterally administered gentamicin into the cerebrospinal fluid in experimental meningitis
140. Efficacy of aserosolised tobramycin in patients with cystic fibrosis
141. Longterm tobramycin aerosol therapy in cystic fibrosis
142. Longterm effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa
143. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
144. Serum protein binding of aminoglycoside antibiotics
145. Azithromycin and clarithromycin
146. The new macrolides azithromycin and clarithromycin
147. New macrolide antibiotics: Azithromycin and clarithromycin
148. Chemistry and mode of action of macrolides
149. Semi-synthetic derivatives of erythromycin
150. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides
151. The macrolides: Erythromycin, clarithromycin, and azithromycin
152. Comparative in vitro activity of the new oral macrolide azithromycin
153. Clinical microbiology of azithromycin
154. In vitro activity of azithromycin against bacterial enteric pathogens
155. Bacteriostatic and bactericidal activities of 24 antimicrobial agents against campylobacter foetus subsp. jejuni
156. In vitro evaluation of activities of azithromycin, erythromycin and tetracycline against chlamydia trachomatis and chlamydia pneumoniae
157. In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against chlamydia pneumoniae
158. Spectrum of activity of azithromycin
159. Enhancement of the in vitro and in vivo activities of clarithromycin against haemophillus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans
160. In vitro activity of 12 orally administered antimicrobial agents against four species of respiratory pathogens from US medical centers in 1992 and 1993
161. In vitro susceptibilities of 180 clinical isolates of haemophillus influenzae to ampicilin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin and azithromycin
162. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin, and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum
163. In vitro and in vivo activities of macrolides against mycoplasma pneumoniae
164. Comparative susceptibility of legionella pneumophila and legionella longbeachae to 12 antimicrobial agents
165. In vitro activities of azithromycin, clarithromycin, erythromycin and tetracycline against 13 strains of chlamydia pneumoniae
166. Evaluation of in vitro spectra of activity of azithromycin, clarithromycin and erythromycin tesyed against strains of neisseria gonorrhoeae by reference agar dilution, disk diffusion, and etest methods
167. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against chlamydia trachomatis
168. In vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against neisseria gonorrhoeae, haemophillus ducreyi and chlamydia trachomatis
169. In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide CP62993, against mycoplasma hominis and ureaplasma urealyticum
170. Comparative in vitro activities of clarithromycin, azithromycin and erythromycin against borrelia burgdorferi
171. In vitro testing of clarithromycin in combination with ethambutol and rifampin against mycobacterium avium complex
172. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against mycobacterium avium complex
173. Azithromycin and clarithromycin
174. Resistance to erythromycin in group A streptococci
175. Influence of imcreased macrolide consumption on macrolide resistance of common respiratory pathogens
176. Susceptibilities of streptococcus pneumoniae and haemophillus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study
177. Transplacental passage of erythromycin and clindamycin
178. Distribution of azithromycin into brain tissue, cerebrospinal fluid and aqueous humor of the eye
179. Azithromycin-review of key chemical, pharmacokinetic and microbiological features
180. Pharmacokinetic properties of the macrolide antibiotics: Effects of age and various pathophysiological states (part I)
181. Pharmacokinetic data and drug monitoring (1): Antibiotics and antiarrhythmics
182. Erythromycin: A review of its uses in pediatric practice
183. Erythromycin pharmacokinetics in man
184. Clarithromycin: Pharmacokinetic and pharmacodynamic interrelationships and dosage regimen
185. Clarithromycin clinical pharmacokinetics
186. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin
187. Pharmacokinetics of a clarithromycin suspension in infants and children
188. Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: An open clinical, microbiological and pharmacokinetic study
189. Azithromycin: A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy
190. The pharmacokinetics of azithromycin in human serum and tissues
191. Azithromycin: Spectrum of activity, pharmacokinetics and clinicla applications
192. Focus on clarithromycin and azithromycin: Two new macrolide antibiotics
193. Breakthrough sepsis in macrolide resistant pneumococcal infection
194. Pneumococcal meningitis during therapy of otitis media with clarithromycin
195. Mycoplasma pneumoniae and chlamydia pneumoniae in paediatric community-acquired pneumonia: Comparative efficacy and safety of clarithromycin vs erythromycin ethylsuccinate
196. Community-acquired pneumonia in adults: Guidelines for management
197. Atypical pneumonias in children
198. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: A prospective, randomized, multicenter trial
199. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP59500 in experimental endocarditis due to staphylococcus aureus
200. Clindamycin
201. Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against staphylococcus aureus, streptococcus pneumoniae, and bacteroides fragilis
202. Clindamycin, metronidazole, and chloramphenicol
203. Pharmacokinetic comparison of three clindamycin phosphate dosing schedules
204. Pharmacokinetic studies of clindamycin phosphate
205. Streptococcal infections of skin and soft tissue
206. Effects of antibiotics on toxin production and viability of Clostridium perfringens
207. Antibiotic effects on bacterial viability, toxin production, and host response
208. In vitro and in vivo effects of penicillin and clindamycin on expression of group A beta-haemolytic streptocaccal capsule
209. Role of newer broad-spectrum β-lactam and fluoroquinolone antibiotics in children
210. Quinolone arthropaty in animals versus children
211. Use of fluoroquinolones in paediatrics: Consensus report of an international society of chemotherapy commision
212. Fluoroquinolones in paediatrics
213. Emergence of drug resistant pneumococcal infections in the United States
214. Trovafloxacin: A new extended-spectrum fluoroquinolone with real potential for the management of infections due to Streptococcus pneumoniae
215. Expanded activity and utility of the new fluroquinolones: A review
216. Grepafloxacin
217. Antibacterial activity of grepafloxacin
218. Levofloxacin, a second-generation fluoroquinolone
219. Levofloxacin: A therapeutic review
220. Fluroquinolone antimicrobial agents
221. Epidemiology of quinolone resistance: Europe, and North and South America
222. Fluoroquinolone pharmacokinetics, pharmacodynamics and drug interactions
223. Moxifloxacin
224. Levofloxacin and sparfloxacin: New quinolone antibiotics
225. Possible role of the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: Review of current information on efficacy and safety
226. Aetioloogy of acute childhood encephalitis at The Hospital for Sick Children, Toronto: 1994-1995
227. The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin
228. Pharmacokinetics of ciprofloxacin after oral and parenteral administration
229. Pharmacokinetics of ciprofloxacin after oral and parenteral administration in healthy volunteers
230. Multiple dose pharmacokinetics and safety of ciprofloxacin in normal volunteers
231. Multiple dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers
232. Ciprofloxacin in preterm neonates: Case report and review of the literature
233. Kinetics of and absorption and elimination of ofloxacin in humans after oral and rectal administration
234. Bioequivalence of oral and intravenous ofloxacin after multiple dose administration to healthy male volunteers
235. Pharmacokinetics of parenteral ofloxacin in volunteers
236. Multiple dose pharmacokinetics of ofloxacin: A new broad spectrum antimicrobial agent
237. Quantitative investigation on renal handling of ofloxacin in man
238. Ofloxacin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use
239. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin
240. The in-vitro activity of OP-17116, a new 5-methyl substituted quinolone
241. Concentration sof OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments
242. Sparfloxacin and other new fluoroquinolones
243. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin
244. The clinical pharmacokinetics of levofloxacin
245. Multiple dose pharmacokinetics and safety of trovafloxacin in healthy volunteers
246. A case of destructive polyarthropaty in a 17 years old youth following pefloxacin treatment
247. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man
248. Pharmacokinetics of grepafloxacin
249. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males
250. Clinical pharmacokinetics of sparfloxacin
251. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
252. Clinical pharmacokinetics of sparfloxacin
253. The clinical pharmacokinetics of levofloxacin
254. Pharmacokinetics of grepafloxacin
255. Trovafloxacin: A new fluoroquinolone
256. Quinolone pharmacokinetics and metabolism
257. Pharmacokinetics of single dose ciprofloxacin in infants and small children
258. Pharmacokinetic studies of ciprofloxacin in children with cystic fibrosis
259. Interactions of quinolones with other drugs. Mecanisms, variability, clinical significance and management
260. Effect of maalox and omeprazole on the bioavailability of trovafloxacin
261. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium
262. The quinolones: An overview of their pharmacology
263. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis
264. Levofloxacin: Its use in infections of the respiratory tract, skin, soft tissues and urinary tract
265. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy
266. Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes
267. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses
268. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibreoptic bronchoscopy
269. Ciprofloxacin therapy in cystic fibrosis
270. Prevention of chronic pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
271. Ciprofloxacin in the treatment of pseudomonas infection in children with cystic fibrosis
272. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients
273. Use of ciprofloxacin versus aminoglycosides for therapy of complicated urinary tract infection: Prospective, randomised clinical and pharmacokinetic study
274. Using quinolones in urinary tract infections in children
275. Evaluation of norfloxacin in the paediatric field: Paediatric study group for norfloxacin
276. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: Preliminary experience in 21 children
277. Trovafloxacin in the treatment of intra-abdominal infections: Results of a double-blind, multicenter comparison with imipenem/cilastatin: Tovafloxacin Surgical Group
278. The changing epidemiology of bacteremia in neutropenic children with cancer
279. Epidemiology and management of paediatric febrile cancer patients
280. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
281. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
282. Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin
283. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis
284. Moxifloxacin in the therapy of experimental pneumococcal meningitis
285. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by penicillin-resistant Pneumococcus in rabits
286. Antibiotics in the mangement of shigellosis in children: What dose for the quinolones
287. Pharmacokinetics of ofloxacin and the effect on faecal flora on healthy volunteers
288. An open study of ciprofloxacin for the treatment of proven or suspected extra-intestinal salmonellosis in African children
289. Amphotericin A and B, antifungal antibiotics produced by a streptomycete, I: In vitro studies
290. New antifungal compounds and strategies for treatment of invasive fungal infections in patients with neoplastic diseases
291. Treatment of fungal infections with semisynthetic derivatives of amphotericin B alpha
292. Amphotericin B: Current understanding of mechanisms of action
293. Amphotericin B: 30 Years of experience
294. Using amphotericin B in the critically ill: A new look at an old drug
295. Pharmacokinetics of amphoterin B in children
296. Antifungal agents. Amphotericin B preparations and flucytosine
297. Liposomal and lipid formulations of amphotericin B: Clinical pharmacokinetics
298. Comparative safety, tolerance and pharmacokinetics of amphotericin lipid complex and amphotericin dexoycholate in healthy male volunteers
299. Pharmacokinetics of liposomal amphotericin B (Ambisome) versus other lipid based formulations
300. Liposomales amphotericin B
301. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
302. Empiric treatment of fungal infections in the neutropenic host
303. The child with cancer and infection. II. Nonbacterial infections
304. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
305. Infections in bone marrow transplant recipients
306. Successful program to prevent aspergillus infections in children undergoing marrow transplantation: Use of nasal amphotericin
307. Strategies to prevent or control infections after bone marrow transplants
308. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology
309. Succesful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion. Report of four cases
310. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates
311. Management of neonatal candidiasis
312. Amphotericin B nephrotoxicity
313. Nephrotoxicity of amphotericin B with emphasis on changes in tubular function
314. Sodium chloride treatment of amphotericin B nephrotoxicity: Standard of care?
315. Lipid formulations of amphotericin B: Recent progress and future directions
316. Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation
317. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
318. Rhinocerebral mucormycosis therapy with amphotericin B lipid complex
319. Mucormycosis (zygomycosis): Is there news for the clinician?
320. Rhinocerebral and systemic mucormycosis. Clinical experience with 36 cases
321. Rhinocerebral mucormycosis: Use of liposomal amphotericin B
322. Lipid-based amphotericin B in the treatment of cryptococcosis
323. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
324. Antifungal agents. Part II. The azoles (symposium on antimicrobial agents - Part IV)
325. Increased gastric pH and the bioavailability of fluconazole and ketoconazole
326. Pharmacokinetics and tissue penetration of fluconazole in humans
327. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS
328. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: Case report
329. Fluconazole penetration in cerebral parenchyma in humans at steady state
330. Fluconazole penetration into the human prostate
331. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis
332. Flluconazole penetration into cerebrospinal fluid: Implications for treating fungal infections of the central nervous system
333. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans
334. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: Successful treatment with fluconazole, a new orally active antifungal agent
335. The use of fluconazole in the management of Candida peritonitis in patients on peritoneal dialysis
336. Treatment of fungal peritonitis complicating continuous ambulatory peritoneal dialysis with oral fluconazole: A series of 21 patients
337. Fluconazole in the management of fungal urinary tract infections
338. Yeast in the urine: Solutions for a budding problem
339. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infection in elderly patients
340. A randomised trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
341. Fluconazole versus amphotericin in the treatment of hematogenous candidiasis: A matched cohort study
342. Management of invasive candidal infections: Results of a prospective, randomised, multicenter study of fluconazole versus amphotericin and review of the literature
343. Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes
344. Problems and controversies in the management of hematogenous candidiasis
345. Resistance of candida species to fluconazole
346. Increase in candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
347. Recent advances in the management of cryptococcal meningitis in patients with AIDS
348. Role of azoles in antifungal therapy
349. Fluconazole therapy for coccidioidal meningitis
350. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections
351. Antifungal agents
352. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits
353. Treatment of invasive aspergillosis with itraconazole
354. Pharmacokinetics of oral antifungals and their clinical implications